US Patents in Excipients, Delivery and Release of Pharmaceutical
Compositions and Actives Granted in 2010

Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENTS IN PHARMACEUTICAL EXCIPIENTS AND FORMULATION GRANTED IN 2010



Patent No.: US7645759B2  Issued: 12/Jan/2010

Title: Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom

Applicant/Assignee: ISTITUTO LUSO FARMACO D'ITALIA S.P.A

Application No.: 11/786041   Filing Date: 10/Apr/2007

Abstract:

Non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor are disclosed. The compounds have the general formula (I) in which R is hydrogen or methyl

W is a single bond or an oxygen atom

n=3

X is hydrogen or a -NR1R2 amino group in which R1 and R2 can be independently hydrogen or a group which is methyl, ethyl, n-propyl, or isopropyl

Y is a -NR3R4R5 quaternary ammonium group in which R3, R4, R5 can be independently a group which is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or n-pentyl

and the enantiomers and enantiomeric mixtures thereof. Pharmaceutical compositions containing these compounds and methods of using the compounds to treat patients having conditions, disorders or diseases involving activation of bradykinin B2 receptors are also disclosed.

Priority: IT2004MI01963 Applic. Date: 2004-10-15; WO2005EP10412 Applic. Date: 2005-09-27

Inventor: FELICETTI PATRIZIA [IT]; FINCHAM CHRISTOPHER INGO [IT]; GIOLITTI ALESSANDRO [IT]; MAGGI CARLO ALBERTO [IT]; QUARTARA LAURA [IT]; ROSSI CRISTINA [IT]


Patent No.: US7645767B2  Issued: 12/Jan/2010

Title: Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy

Applicant/Assignee: TRINITY LABORATORIES, INC

Application No.: 11/892422   Filing Date: 22/Aug/2007

Abstract:

Chronic pain is alleviated in a mammal suffering there from by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, in combination with a mu-opiate analgesic such as tramadol or an analogously acting molecular entity, and a capsaicin or an ester of capsaicin, and optionally in sustained release dosage form.

Priority: US20060841225P Applic. Date: 2006-08-31

Inventor: SINGH CHANDRA ULAGARAJ [US]; WOODY DAVID LLOYD [US]; NULU JAGAVEERABHADRA RAO [US]


Patent No.: US7655697B2  Issued: 02/Feb/2010

Title: Oral Pharmaceutical Composition for Targeted Transport of a Platinum Complex Into the Colorectal Region, Method for Producing and Use as Medicament Thereof

Applicant/Assignee: PLIVA-LACHEMA A.S

Application No.: 11/574929   Filing Date: 14/Sep/2005

Abstract:

An oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, includes a mixture of platinum complex of general formula I wherein A each independently is an -NH3 group or an amino group containing 1 to 18 carbon atoms, B each independently is a halogen atom, a hydroxy group or a -O-C(O)-R group wherein R each independently is hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group containing 1 to 10 carbon atoms or functional derivatives of these groups, and X each independently is a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X together form a dicarboxylate group containing 2 to 20 carbon atoms, and at least one excipient selected from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide mucopolysaccharide, protein, oligoprotein, polyprotein,

mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, which mixture is optionally compressed into a tablet or contained in a capsule, and this tablet or capsule is optionally coated with a biodegradable layer and/or an outer pH-sensitive colonic layer, and a method of manufacturing and using the composition for treatment of colorectal carcinoma.

Priority: CZ20040000964 Applic. Date: 2004-09-14; WO2005CZ00070 Applic. Date: 2005-09-14

Inventor: FRANC ALES [CZ]; SOVA PETR [CZ]


Patent No.: US7658938B2  Issued: 09/Feb/2010

Title: Solid oral dosage form containing an enhancer

Applicant/Assignee: MERRION REASEARCH III LIMITED

Application No.: 09/510560   Filing Date: 22/Feb/2000

Abstract:

The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.

Priority: US19990121048P Applic. Date: 1999-02-22

Inventor: CUMMING KENNETH IAIN [IE]; RAMTOOLA ZEBUNNISSA [IE]


Patent No.: US7658944B2  Issued: 09/Feb/2010

Title: Solid dosage form comprising a fibrate

Applicant/Assignee: LIFECYCLE PHARMA A/S

Application No.: 10/513807   Filing Date: 08/Nov/2004

Abstract:

The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.

Priority: DK20030001503 Applic. Date: 2003-10-10; DK20040000464 Applic. Date: 2004-03-23; DK20040001006 Applic. Date: 2004-06-25; WO2004DK00667 Applic. Date: 2004-10-01

Inventor: HOLM PER [DK]; NORLING TOMAS [DK]


Patent No.: US7662364B2  Issued: 16/Feb/2010

Title: Drug for Hyperphospheremia and Its Preparative Method

Applicant/Assignee:

Application No.: 11/576731   Filing Date: 26/Jun/2006

Abstract:

This invention reports a drug for hyperphospheremia and its preparative method. The preparation includes active constituents, lanthanum polystyrene sulfonate, and excipients. The preparative method in the invention can be summarized as follows: Polystyrene sulfonic acid is obtained by treating polystyrene sulfosalt with hydrochloric acid, soaked or eluted with water soluble lanthanum-contained solution, and washed with water till its PH is neutral. Then, the lanthanum polystyrene sulfonate solution is washed till the superfluous La- unexchanged is washed out. Lanthanum polystyrene sulfonate is taken out and crushed to powder after being dried. The lanthanum polystyrene sulfonate, whose weight percentage of lanthanum is 14-22%, is used as active constituents to prepare gastrointestinal tract preparations together with general amount of excipients with routine preparative method.

In the invention, lanthanum polystyrene sulfonate is adopted as active constituents, mixed with excipients, and the preparation is obtained. It makes phosphate in alimentary tract become insoluble conjugates after gastrointestinal tract administration. The insoluble conjugates would be discharged. Thus, the drug can achieve the purpose of treating hyperphospheremia.

Priority: CN20061043267 Applic. Date: 2006-03-24; WO2006CN01463 Applic. Date: 2006-06-26

Inventor: LI SHI BIAO [CN]; QIAO MIN [CN]; ZHANG WEI SHENG [CN]


Patent No.: US7666403B2  Issued: 23/Feb/2010

Title: Mutant interferon [alpha] protein and use thereof

Applicant/Assignee: KABUSHIKI KAISHA HAYASHIBARTA SEIBUTSU KAGAKI KAGAKU KEBKYUJO KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO

Application No.: 11/719283   Filing Date: 09/Nov/2005

Abstract:

The present invention has objects to provide a mutant interferon-[alpha] protein having a higher anti-viral and anti-tumor activity and to provide an agent for susceptive diseases, which contains the mutant interferon-[alpha] protein as an effective ingredient

and solves the above objects by providing a mutant protein which has an amino acid sequence of human interferon-[alpha] subtype [alpha]8 represented by any one of SEQ ID NOs:1 to 3, where the arginine residue at the 145th has been replaced with leucine, isoleucine, or valine residue

the alanine residue at the 146th has been replaced with asparagine or serine residue

and the methionine residue at the 149th has been replaced with tyrosine residue

and an agent for susceptive diseases, containing the mutant protein.

Priority: JP20040329461 Applic. Date: 2004-11-12; WO2005JP20514 Applic. Date: 2005-11-09

Inventor: MAYUMI TADANORI [JP]; TSUTSUMI YASUO [JP]; NAKAGAWA SHINSAKU [JP]; TANIAI MADOKA [JP]; TORIGOE KAKUJI [JP]; KURIMOTO MASASHI [JP]


Patent No.: US7666838B2  Issued: 23/Feb/2010

Title: Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes

Applicant/Assignee: UUTECH LIMITED

Application No.: 12/001449   Filing Date: 11/Dec/2007

Abstract:

The present invention provides peptides which stimulate the release of insulin. The peptides, based on GIP 1-42 include substitutions and/or modifications which enhance and influence secretion and/or have enhanced resistance to degradation. The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes.

Priority: GB19990007216 Applic. Date: 1999-03-29; GB19990017565 Applic. Date: 1999-07-27; US2005-090825 Applic. Date: 2005-03-25; US2002-937687 Applic. Date: 2002-01-08; WO2000GB01089 Applic. Date: 2000-03-29

Inventor: O'HARTE FINBARR PAUL [GB]; FLATT PETER RAYMOND [GB]


Patent No.: US7666909B2  Issued: 23/Feb/2010

Title: Enhancement of alcohol metabolism

Applicant/Assignee:

Application No.: 11/105022   Filing Date: 13/Apr/2005

Abstract:

D-glyceric acid has been found to enhance alcohol metabolism and thereby prevent adverse effects of alcohol consumption. D-glyceric acid is administered concurrently with alcohol, to accelerate the elimination of the alcohol from the body. D-glyceric acid is converted into D-glyceraldehyde and further into glycerol in reactions catalysed by NADH-aldehyde dehydrogenase and NADH-alcohol dehydrogenase complexes, which are produced in excess during alcohol oxidation, in the cells of alcohol-metabolising tissues. In these reactions, the NADH complexes become NAD-aldehyde dehydrogenase and NAD-alcohol dehydrogenase complexes. These complexes in turn accelerate the oxidation of alcohol, which is paralleled by enhancement of acetaldehyde oxidation to metabolically harmless acetic acid.

D-glyceric acid or its salt or ester is used for the manufacture of a pharmaceutical preparation for enhancing the metabolism of alcohol. A method of enhancing the metabolism of alcohol in a subject by administering said compounds an effective amount of D-glyceric acid or its salt or ester is disclosed. An oral or parenteral preparation comprising said compounds is also disclosed.

Priority: FI20020001819 Applic. Date: 2002-10-14

Inventor: HEINO PEKKA [FI]


Patent No.: US7670612B2  Issued: 02/Mar/2010

Title: Multi-phase, multi-compartment capsular delivery apparatus and methods for using same

Applicant/Assignee: INNERCAP TECHNOLOGIES, INC

Application No.: 10/804576   Filing Date: 19/Mar/2004

Abstract:

A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral

and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral

wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber

and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber.

Priority: WO2003US10816 Applic. Date: 2003-04-09; US20020371448P Applic. Date: 2002-04-10

Inventor: MILLER FRED H [US]


Patent No.: US7671044B2  Issued: 02/Mar/2010

Title: Pharmaceutical formula for treating skin disease

Applicant/Assignee: KLEVER MODE, S.L

Application No.: 11/521073   Filing Date: 14/Sep/2006

Abstract:

The present invention refers to a pharmaceutical formulation characterized in that it includes mainly clobetasolpropionate, minoxidil and 11 alpha hydroxyprogesterone as main active principles, besides other excipients, vitamins and/or minerals, and to its use in the treatment of skin diseases, mainly in the symptomatic treatment of psoriasis.

Priority: EP20060380229 Applic. Date: 2006-08-17

Inventor: BARRANCO ENRIQUE ROSSELL [ES]


Patent No.: US7674480B2  Issued: 09/Mar/2010

Title: Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD

Application No.: 09/887204   Filing Date: 22/Jun/2001

Abstract:

The present invention provides a pharmaceutical composition for use in a dosage form for oral administration to a patient. The composition expands upon contact with gastric fluid and promotes retention of the dosage form in the patient's stomach for a prolonged period of time. The present invention further provides pharmaceutical dosage forms containing an active ingredient, and the pharmaceutical composition. The forms are adapted for immediate or controlled release of the active ingredient. The dosage forms may be used advantageously in the treatment of Parkinson's disease with levodopa and hyperactivity and attention deficit disorder with methylphenidate.

Priority: US20000213832P Applic. Date: 2000-06-23; US20000217110P Applic. Date: 2000-07-10; US20000223212P Applic. Date: 2000-08-04

Inventor: FLESHNER-BARAK MOSHE [IL]; LERNER E ITZHAK [IL]; ROSENBERGER VERED [IL]; DAHAN MAZAL [IL]; MAKOV YISRAEL [IL]


Patent No.: US7674799B2  Issued: 09/Mar/2010

Title: Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone

Applicant/Assignee: EURO-CELTIQUE S.A PURDUE PHARMA L.P

Application No.: 11/653531   Filing Date: 16/Jan/2007

Abstract:

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.

Priority: US2006-391897 Applic. Date: 2006-03-29; US2005-093626 Applic. Date: 2005-03-30; US20040557492P Applic. Date: 2004-03-30; US20040601534P Applic. Date: 2004-08-13; US20040620072P Applic. Date: 2004-10-18; US20050648625P Applic. Date: 2005-01-31; US20050651778P Applic. Date: 2005-02-10

Inventor: CHAPMAN ROBERT [US]; RIDER LONN S [US]; HONG QI [US]; KYLE DONALD [US]; KUPPER ROBERT [US]


Patent No.: US7678366B2  Issued: 16/Mar/2010

Title: Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues

Applicant/Assignee: TARO PHARMACEUTICAL INDUSTRIES LIMITED

Application No.: 11/313186   Filing Date: 20/Dec/2005

Abstract:

A topical sustained release delivery system for delivery of antifungal agents to the finger or toenails achieving high penetration through the nails by combining the antifungal agent with a keratolytic agent and a humectant. The pharmaceutical sustained release topical preparation is provided in a varnish or spray form for treating the nail and surrounding tissues, where the active ingredient is an antifungal agent, a keratolytic agent, or preferably a combination of an antifungal and a keratolytic agent. The composition may further comprise an antibacterial, an antiviral, an antipsoriatic agents, or combinations thereof.

Priority: US2000-534960 Applic. Date: 2000-03-27

Inventor: FRIEDMAN MICHAEL [IL]; LICHT DANIELLA [IL]; YACOBI AVRAHAM [US]


Patent No.: US7682632B2  Issued: 23/Mar/2010

Title: Tamper-resistant oral opioid agonist formulations

Applicant/Assignee: PURDUE PHARMA L.P

Application No.: 10/700906   Filing Date: 04/Nov/2003

Abstract:

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.

Priority: US2001-781081 Applic. Date: 2001-02-08; US20000181369P Applic. Date: 2000-02-08

Inventor: OSHLACK BENJAMIN [US]; WRIGHT CURTIS [US]; HADDOX J DAVID [US]


Patent No.: US7683038B2  Issued: 23/Mar/2010

Title: Percarboxylated polysaccharides, and a process for their preparation

Applicant/Assignee: FIDIA FARMACEUTICI S.P.A

Application No.: 10/376369   Filing Date: 28/Feb/2003

Abstract:

The present invention relates to percarboxylated polysaccharide selected from the group consisting of gellan, carboxymethylcellulose, pectic acid, pectin and hyaluronic acid derivatives

the process for their preparation and their use in the pharmaceutical, biomedical, surgical and healthcare fields.

Priority: WO2001EP10062 Applic. Date: 2001-08-31; IT2000PD00208 Applic. Date: 2000-08-31

Inventor: BELLINI DAVIDE [IT]; CRESCENZI VITTORIO [IT]; FRANCESCANGELI ANDREA [IT]


Patent No.: US7683050B2  Issued: 23/Mar/2010

Title: Formulations and methods of administration of cephalotaxines, including homoharringtonine

Applicant/Assignee: CHEMGENEX PHARMACEUTICALS, INC

Application No.: 11/497739   Filing Date: 01/Aug/2006

Abstract:

The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of homoharringtonine for the treatment of cancer and other aberrant cellular diseases. The invention also provides methods and compositions for antiparasitic, antifungal, antiviral and antibacterial treatments.

Priority: US2003-617927 Applic. Date: 2003-07-10; US20020396926P Applic. Date: 2002-07-17

Inventor: BROWN DENNIS M [US]


Patent No.: US7683095B2  Issued: 23/Mar/2010

Title: Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones

Applicant/Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE KGK SYNERGIZE, INC

Application No.: 10/854063   Filing Date: 26/May/2004

Abstract:

Compositions and methods for the treatment, reduction and/or prevention of cardiovascular diseases and disorders are described. Individuals at high risk for developing or having cardiovascular disease or disorder may be treated with an effective dose of a polymethoxyflavone including limocitrin derivatives, quercetin derivatives, naturally occurring polymethoxyflavones, tocotrienols, and mixtures of these compounds.

Priority: US2000-528488 Applic. Date: 2000-03-17; US1998-167634 Applic. Date: 1998-10-06

Inventor: GUTHRIE NAJLA [CA]; KUROWSKA ELZBIETA MARIA [CA]; MANTHEY JOHN A [US]


Patent No.: US7691411B2  Issued: 06/Apr/2010

Title: Pharmaceutical formulae for thyroid hormones and procedures for obtaining them

Applicant/Assignee: ALTERGON S.A

Application No.: 10/746386   Filing Date: 23/Dec/2003

Abstract:

The present invention provides pharmaceutical formulation for thyroid hormones which allow safe and stable administration by mouth within the ambit of the narrow therapeutic index prescribed in the case of thyroid dysfunctions, as well as procedures for obtaining them.

Priority: IT2002MI02777 Applic. Date: 2002-12-27

Inventor: DI MARTINO ALESSANDRO [IT]; MATEO ANGEL [IT]; GARAVANI ALBERTO [CH]; MARCHIORRI MAURIZIO [IT]


Patent No.: US7691806B2  Issued: 06/Apr/2010

Title: Repeat sequence protein polymer active agent congjugates, methods and uses

Applicant/Assignee: GENENCOR INTERNATIONAL, INC

Application No.: 11/351712   Filing Date: 10/Feb/2006

Abstract:

Biomolecular conjugates are provided which comprise the conjugation product of a repeat sequence protein polymer and at least one active agent. Additional aspects provide methods for their manufacture and various industrial and consumer applications.

Priority: US2004-845936 Applic. Date: 2004-05-14; US20030470464P Applic. Date: 2003-05-14

Inventor: COLLIER KATHERINE D [US]; CUEVAS WILLIAM A [US]; KUMAR MANOJ [US]


Patent No.: US7695528B2  Issued: 13/Apr/2010

Title: Calcium Carbonate Granulation

Applicant/Assignee: DELAVAU LLC

Application No.: 11/675459   Filing Date: 15/Feb/2007

Abstract:

Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.

Priority: US2003-631923 Applic. Date: 2003-07-31

Inventor: LANG KEVIN W [US]; LEVIN RAYA [US]; DIBBLE JAMES W [US]; MURPHY GREGORY B [US]


Patent No.: US7696149B2  Issued: 13/Apr/2010

Title: Pharmaceutical administration form for peptides, process for its preparation, and use

Applicant/Assignee: AETERNA ZENTARIS GMBH

Application No.: 11/028875   Filing Date: 04/Jan/2005

Abstract:

A method for preventing aggregation of an LHRH antagonist in a pharmaceutical composition. The method comprises combining the LHRH antagonist in the form of an acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salt and at least one of the acids for forming the salts in free acid form.

Priority: DE20001024451 Applic. Date: 2000-05-18; US2001-861009 Applic. Date: 2001-05-18

Inventor: BAUER HORST [DE]; DAMM MICHAEL [DE]; SARLIKIOTIS WERNER [GR]


Patent No.: US7700576B2  Issued: 20/Apr/2010

Title: Pharmaceutical Composition on Basis of Reverse Transcriptase Inhibitor and Meldonium

Applicant/Assignee: LATVIAN INSTITUTE OF ORGANIC SYNTHESIS

Application No.: 11/990285   Filing Date: 08/Aug/2006

Abstract:

Novel pharmaceutical compositions which contain one of the reverse transcriptase inhibitors, viz., Zidovudine, Lamivudine or Stavudine in clinically efficacious amount and Meldonium as well as pharmaceutically applicable excipients. It has been proved that inclusion of Meldonium in these pharmaceutical compositions essentially diminishes the cardio- and neuro-toxicity of the reverse transcriptase inhibitor.

Priority: LV20050000095 Applic. Date: 2005-08-15; WO2006LV00005 Applic. Date: 2006-08-08

Inventor: KLUSHA VIJA [LV]; ISAJEVS SERGEJS [LV]; PUPURE JOLANTA [LV]; RUMAKS JURIS [LV]; GORDJUSHINA VALENTINA [LV]; TAIVANS IMMANUELS [LV]; KALVINSH IVARS [LV]


Patent No.: US7704977B2  Issued: 27/Apr/2010

Title: Solid Oral Dosage Form Containing an Enhancer

Applicant/Assignee: MERRION RESEARCH II LIMITED MERRION RESEARCH III LIMITED

Application No.: 11/733007   Filing Date: 09/Apr/2007

Abstract:

The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.

Priority: US20060791231P Applic. Date: 2006-04-07

Inventor: LEONARD THOMAS W [US]


Patent No.: US7708978B2  Issued: 04/May/2010

Title: Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders

Applicant/Assignee: BEIJING JIANKAI TECHNOLOGY CO., LTD

Application No.: 10/514492   Filing Date: 01/Aug/2005

Abstract:

The present invention relates to an active targeted water-solubility macromolecule polymer, conjugate with interferon and pharmaceutical composition comprising the conjugate. The targeted agent includes, for example, glucose, galatose and the like, as well as their derivates. The conjugate of the present invention is well in water-solubility and have long physiological cycle half-life period, and have specific recognition to pathology organize, improved and increased medication effect of interferon to Hepatitis B, Hepatitis C etc. infectivity sickness and cancer, infect complication etc.

Priority: WO2002CN00331 Applic. Date: 2002-05-14; WO2002CN00919 Applic. Date: 2002-12-27

Inventor: JI SHISHAN [CN]; ZHU DEQUAN [CN]


Patent No.: US7713547B2  Issued: 11/May/2010

Title: Method of administering a partial dose of a segmented pharmaceutical tablet

Applicant/Assignee: ACCU-BREAK PHARMACEUTICALS, INC

Application No.: 11/441456   Filing Date: 25/May/2006

Abstract:

A drug-containing pharmaceutical tablet adapted for accurate breaking which has two or more segments with at least one segment containing a drug.

Priority: WO2005US18633 Applic. Date: 2005-05-23; WO2005US18638 Applic. Date: 2005-05-23; WO2005US18639 Applic. Date: 2005-05-23; US20040573042P Applic. Date: 2004-05-21; US20040573134P Applic. Date: 2004-05-21

Inventor: SOLOMON LAWRENCE [US]; KAPLAN ALLAN S [US]


Patent No.: US7713548B2  Issued: 11/May/2010

Title: AMORPHOUS SOLID DISPERSIONS

Applicant/Assignee: SANOFI-AVENTIS U.S. LLC

Application No.: 12/029691   Filing Date: 12/Feb/2008

Abstract:

Disclosed are amorphous solid dispersion formulations comprising 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide.

Priority: WO2006US33022 Applic. Date: 2006-08-24; US20050712150P Applic. Date: 2005-08-29

Inventor: JACOBS IRWIN C [US]; HIGGINS JOHN D [US]; GUILLOT MICAEL [US]; FRANSON NANCY M [US]; ROCCO WILLIAM L [US]; ABU-IZZA KHAWLA ABDULLAH [US]


Patent No.: US7713959B2  Issued: 11/May/2010

Title: Compositions of an anticonvulsant and mirtazapine to prevent weight gain

Applicant/Assignee: DUKE UNIVERSITY

Application No.: 11/216904   Filing Date: 31/Aug/2005

Abstract:

Disclosed are pharmaceutical compositions comprising mirtazapine and an anticonvulsant drug. Also disclosed are methods of preventing weight gain associated with the administration of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug. Further disclosed are methods of increasing the efficacy of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug.

Priority: US2005-034316 Applic. Date: 2005-01-11; US20040616393P Applic. Date: 2004-10-05; US20040567896P Applic. Date: 2004-05-03; US20040535799P Applic. Date: 2004-01-13

Inventor: KRISHNAN K RANGA R [US]; GADDE KISHORE M [US]


Patent No.: US7718599B2  Issued: 18/May/2010

Title: Pharmaceutical administration form for peptides, process for its preparation, and use

Applicant/Assignee: AETERNA ZENTARIS GMBH

Application No.: 09/861009   Filing Date: 18/May/2001

Abstract:

The invention relates to pharmaceutical compositions suitable for parenteral administration comprising, peptides in the form of acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salts in dissolved or dispersed form and at least one of the acids for forming the salts in free acid form.

Priority: DE20001024451 Applic. Date: 2000-05-18

Inventor: BAUER HORST [DE]; DAMM MICHAEL [DE]; SARLIKIOTIS WERNER [GR]


Patent No.: US7727551B2  Issued: 01/Jun/2010

Title: Oral pharmaceutical compositions with modified release of the active ingredient

Applicant/Assignee: FARMATRON LTD

Application No.: 10/482461   Filing Date: 17/Jun/2004

Abstract:

The present invention relates to modified-release oral pharmaceutical compositions containing one or more active principles solubilized, suspended or embedded in a suitably formulated amphiphilicmatrix which, loaded in hydrophilic matrices, provides different release profiles.

Priority: WO2002EP06749 Applic. Date: 2002-06-19; IT2001MI01337 Applic. Date: 2001-06-26

Inventor: MASSIRONI MARIA GABRIELLA [GB]


Patent No.: US7727557B2  Issued: 01/Jun/2010

Title: Pharmaceutical formulation containing irritant

Applicant/Assignee: PURDUE PHARMA L.P PURDUE PHARMA LP

Application No.: 11/525395   Filing Date: 22/Sep/2006

Abstract:

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse

and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.

Priority: US2002-214410 Applic. Date: 2002-08-06; US2002-213920 Applic. Date: 2002-08-06; US2002-214412 Applic. Date: 2002-08-06; US20010310535P Applic. Date: 2001-08-06; US20010310534P Applic. Date: 2001-08-06; US20010310514P Applic. Date: 2001-08-06

Inventor: SACKLER RICHARD [US]


Patent No.: US7727558B2  Issued: 01/Jun/2010

Title: POLYMERIC DELIVERY AGENTS AND DELIVERY AGENT COMPOUNDS

Applicant/Assignee: VIRGINIA COMMONWEALTH UNIVERSITY EMISPHERE TECHNOLOGIES, INC

Application No.: 11/669649   Filing Date: 31/Jan/2007

Abstract:

Polymeric delivery agents, delivery agent compounds and compositions comprising them which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Priority: US2003-447608 Applic. Date: 2003-05-28; US2001-889005 Applic. Date: 2001-10-09; WO2000US00476 Applic. Date: 2000-01-07; US19990115273P Applic. Date: 1999-01-08

Inventor: MILSTEIN SAM J [US]; BARANTSEVITCH EUGENE N [US]; WANG NAI FANG [US]; LIAO JUN [US]; SMART JOHN [US]; CONTICELLO RICHARD [US]; OTTENBRITE RAPHAEL [US]


Patent No.: US7727962B2  Issued: 01/Jun/2010

Title: Powder comprising new compositions of oligosaccharides and methods for their preparation

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Application No.: 11/119957   Filing Date: 02/May/2005

Abstract:

The present invention concerns powders containing a pharmaceutical active substance and a combination of excipients comprising at least one 1,4 O-linked saccharose derivative selected from the compounds: 1,4 O-linked D-Gal-saccharose (lactosucrose), 1,4 O-linked D-Glu-saccharose (glucosyl sucrose), or 1,4 O-linked Glu-Glu-saccharose (maltosyl sucrose) in combination with at least one further excipient. The other excipient is preferably an amino acid, a peptide and/or a mono-, di- and/or oligosaccharide, wherein the oligosaccharide may be a second 1,4 O-linked saccharose derivative, provided that this is different from the first.

Priority: DE200410022928 Applic. Date: 2004-05-10; US20040572306P Applic. Date: 2004-05-18

Inventor: BASSARAB STEFAN [DE]; BECHTOLD-PETERS KAROLINE [DE]; FUHRHERR RICHARD [DE]; FRIESS WOLFGANG [DE]; GARIDEL PATRICK [DE]; SCHULTZ-FADEMRECHT TORSTEN [DE]


Patent No.: US7727987B2  Issued: 01/Jun/2010

Title: Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride

Applicant/Assignee: MERCK EPROVA AG

Application No.: 10/990316   Filing Date: 17/Nov/2004

Abstract:

Crystal forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride, hydrates and solvates and processes for their preparation are provided. These crystal forms are either intermediates for the preparation of stable polymorphic form B or are suitable for solid formulations.

Priority: US20030520377P Applic. Date: 2003-11-17

Inventor: MOSER RUDOLF [CH]; GROEHN VIOLA [CH]; EGGER THOMAS [CH]; BLATTER FRITZ [CH]


Patent No.: US7728169B2  Issued: 01/Jun/2010

Title: PHARMACEUTICAL COMPOSITIONS OF ISOLATED ORTHORHOMBIC CRYSTALLINE 4-[6-ACETYL-3-[3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENYLTHIO)PROPOXY]-2-PROPYLPHENOXY]BUTYRIC ACID AND METHODS OF USE

Applicant/Assignee: MEDICINOVA, INC

Application No.: 12/106939   Filing Date: 21/Apr/2008

Abstract:

A pharmaceutical composition comprising a compound of formula (1) in polymorphic crystalline Form A: together with a pharmaceutically acceptable carrier or excipient, wherein the compound of formula (1) is present in polymorphic Form A (see, e.g., FIG. 6) substantially free of other polymorphic forms.

Priority: US2005-319272 Applic. Date: 2005-12-29; US2003-601862 Applic. Date: 2003-06-24

Inventor: LOCKE KENNETH WALTER [US]; ROE DAVID GREGORY [CA]


Patent No.: US7731967B2  Issued: 08/Jun/2010

Title: Compositions for inducing immune responses

Applicant/Assignee: NOVARTIS VACCINES AND DIAGNOSTICS, INC

Application No.: 10/837117   Filing Date: 29/Apr/2004

Abstract:

The invention provides, inter alia, immunogenic compositions comprising a first antigen, at least two adjuvants, wherein a first adjuvant comprises a polymer derived from poly(lactides) and/or poly(lactide-co-glycolides), and wherein a second adjuvant comprises an imidazoquinoline, wherein said first antigen is encapsulated within, adsorbed or conjugated to, co-lyophilized or mixed with said first adjuvant, and a pharmaceutically acceptable excipient, wherein said composition elicits a cellular immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions, methods for producing a cytotoxic-T lymphocyte (CTL) response in a vertebrate subject, and methods of immunization.

Priority: US20030466948P Applic. Date: 2003-04-30

Inventor: O'HAGAN DEREK [US]; SINGH MANMOHAN [US]


Patent No.: US7732399B2  Issued: 08/Jun/2010

Title: SUSTAINED RELEASE FORMULATIONS

Applicant/Assignee: AMGEN INC

Application No.: 11/847984   Filing Date: 30/Aug/2007

Abstract:

The present invention relates broadly to the field of sustained release formulations. More specifically, the invention describes compositions and methods relating to formulating proteins and/or peptides with purified gallic acid esters. In one example, the gallic acid ester is PentaGalloylGlucose (PGG) and in anther example the gallic acid ester is epigallocatechin gallate (EGCG).

Priority: US2005-114473 Applic. Date: 2005-04-25; US20040565247P Applic. Date: 2004-04-23

Inventor: GOLDENBERG MERRILL S [US]; GU JIAN HUA [US]


Patent No.: US7736674B2  Issued: 15/Jun/2010

Title: CONTROLLED RELEASE COMPOSITIONS FOR INTERFERON BASED ON PEGT/PBT BLOCK COPOLYMERS

Applicant/Assignee: OCTOPLUS SCIENCES B.V BIOLEX THERAPEUTICS, INC

Application No.: 11/774107   Filing Date: 06/Jul/2007

Abstract:

The invention discloses a pharmaceutical composition for the controlled release of relatively toxic active compounds, in particular for bioactive proteins from the class of interferons. The composition comprises a biodegradable block copolymer constructed from poly(ethylene glycol) terephthalate (PEGT) and poly(butylene terephthalate) (PBT). The composition is provided in the form of injectable microparticles, of an injectable liquid which may have self-gelling properties, or of a solid implant. The invention further provides a pharmaceutical kit comprising the composition, methods for preparing the composition, and the pharmaceutical uses relating thereto.

Priority: EP20050075043 Applic. Date: 2005-01-07; WO2006NL00006 Applic. Date: 2006-01-06

Inventor: BECHET ANNE CHANTAL [NL]; VAN DIJKHUIZEN-RADERSMA RIEMKE [NL]; STIGTER MARTIN [NL]; BEZEMER JEROEN MATTIJS [NL]


Patent No.: US7737116B2  Issued: 15/Jun/2010

Title: MODIFIED AND STABILIZED GDF PROPEPTIDES AND USES THEREOF

Applicant/Assignee: WYETH

Application No.: 11/614702   Filing Date: 21/Dec/2006

Abstract:

Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).

Priority: US2002-071499 Applic. Date: 2002-02-08; US20010267509P Applic. Date: 2001-02-08

Inventor: WOLFMAN NEIL M [US]; KHOR SOO-PEANG [US]; TOMKINSON KATHLEEN N [US]


Patent No.: US7737133B2  Issued: 15/Jun/2010

Title: Formulations and methods of treating inflammatory bowel disease

Applicant/Assignee: AGI THERAPEUTICS LTD

Application No.: 10/930743   Filing Date: 01/Sep/2004

Abstract:

Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.

Priority: US20030499365P Applic. Date: 2003-09-03

Inventor: DEVANE JOHN [IE]; BUTLER JACKIE [IE]


Patent No.: US7740861B2  Issued: 22/Jun/2010

Title: Drug delivery product and methods

Applicant/Assignee: UNIVERSITY OF MASSACHUSETTS

Application No.: 10/869693   Filing Date: 16/Jun/2004

Abstract:

The present invention provides a particulate delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload molecule and a payload trapping molecule. The invention further provides methods of making and methods of using the particulate delivery system.

Priority:

Inventor: OSTROFF GARY R [US]


Patent No.: US7744855B2  Issued: 29/Jun/2010

Title: Method of making particles for use in a pharmaceutical composition

Applicant/Assignee: VECTURA LIMITED

Application No.: 10/312488   Filing Date: 11/Mar/2003

Abstract:

A method for making composite excipient particles for use in a pharmaceutical composition comprises a milling step in which particles of an excipient material are milled in the presence of an additive material. The product particles are of small size and the milling requires relatively low input of time and energy. The composite particles are suitable for use in inhalable pharmaceutical compositions.

Priority: EP20000113608 Applic. Date: 2000-06-27; GB20000029263 Applic. Date: 2000-11-30; WO2001GB01732 Applic. Date: 2001-04-17; WO2001GB02860 Applic. Date: 2001-06-27

Inventor: STANIFORTH JOHN NICHOLAS [GB]; MORTON DAVID ALEXANDER VODDEN [GB]; MUSA ROSELLA [IT]


Patent No.: US7745393B2  Issued: 29/Jun/2010

Title: Minimalist bZIP Proteins and uses thereof

Applicant/Assignee:

Application No.: 11/592186   Filing Date: 03/Nov/2006

Abstract:

The present invention provides minimalist bZIP proteins having a basic region derived from bHLH proteins fused to a leucine zipper dimerization domain derived from bZIP proteins and methods and uses thereof in the treatment of cancer. The present invention also provides pharmaceutical compositions for treating cancer.

Priority: US20050732700P Applic. Date: 2005-11-03

Inventor: SHIN JUMI [CA]


Patent No.: US7745397B2  Issued: 29/Jun/2010

Title: PEPTIDE USEFUL IN IMMUNOMODULATION

Applicant/Assignee: CURETECH LTD MOR-RESEARCH APPLICATIONS LTD

Application No.: 11/957128   Filing Date: 14/Dec/2007

Abstract:

The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.

Priority: IL20010145926 Applic. Date: 2001-10-15; US2006-411832 Applic. Date: 2006-04-27; US2004-821283 Applic. Date: 2004-04-09; WO2002IL00831 Applic. Date: 2002-10-15

Inventor: HARDY BRITTA [IL]; RAITER ANNAT [IL]; KLAPPER LEAH [IL]


Patent No.: US7749532B2  Issued: 06/Jul/2010

Title: Once daily formulations of tetracyclines

Applicant/Assignee: SUPERNUS PHARMACEUTICALS, INC

Application No.: 10/819620   Filing Date: 07/Apr/2004

Abstract:

Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.

Priority: US20030460963P Applic. Date: 2003-04-07; US20040547964P Applic. Date: 2004-02-26

Inventor: CHANG RONG-KUN [US]; RAOUFINIA ARASH [US]; SHAH NIRAJ [US]


Patent No.: US7749536B2  Issued: 06/Jul/2010

Title: Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD

Application No.: 11/354555   Filing Date: 14/Feb/2006

Abstract:

The present invention provides pharmaceutical compositions comprising aliphatic amine polymers such as for example Sevelamer HCl as the active pharmaceutical ingredient, wherein the aliphatica amine polymers are spray granulated. The present invention further provides methods of preparing stable pharmaceutical compositions of aliphatic amine polymers such as for example Sevelamer HCl, preferably in tablets dosage forms.

Priority: WO2006US05274 Applic. Date: 2006-02-14

Inventor: HRAKOVSKY JULIA [IL]; TENENGAUZER RUTH [IL]; IOFFE ALLA [IL]; MOIN-KOTLIAR ELEONORA [IL]


Patent No.: US7749537B2  Issued: 06/Jul/2010

Title: Method of forming a tablet

Applicant/Assignee: SCOLR PHARMA, INC

Application No.: 11/906303   Filing Date: 01/Oct/2007

Abstract:

A method of forming a tablet includes the steps of pre-blending an active pharmaceutical ingredient susceptible to tackiness and a blending additive with a first mixing effort to form a pre-blend mixture, wherein the first mixing effort and a second mixing effort, resulting from mixing at least one excipient with the pre-blend mixture, form a blend suitable for direct compression and compressing the blend to form the tablet. One way of achieving the first mixing effort is to pre-blend for an extended period of time. The method allows for directly compressing the blend without the need for a granulation step or roller compression. One such active pharmaceutical ingredient susceptible to tackiness is ibuprofen.

Priority: US2006-633322 Applic. Date: 2006-12-04

Inventor: HITE MICHAEL [US]; FEDERICI CATHY [US]; BRUNELLE ALAN [US]; TURNER STEPHEN [US]


Patent No.: US7754199B2  Issued: 13/Jul/2010

Title: Pharmaceutical compositions comprising crosslinked amine polymer with repeat units derived from polymerization of tertiary amines

Applicant/Assignee: ILYPSA, INC

Application No.: 11/734152   Filing Date: 11/Apr/2007

Abstract:

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides polymeric and pharmaceutical compositions comprising crosslinked amine polymers. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of renal diseases and hyperphosphatemia.

Priority: US2004-806495 Applic. Date: 2004-03-22

Inventor: CHANG HAN TING [US]; CHARMOT DOMINIQUE [US]; CONNOR ERIC [US]; ROGER FLORENCE [US]


Patent No.: US7758886B2  Issued: 20/Jul/2010

Title: Pharmaceutical aerosol composition

Applicant/Assignee: PARI GMBH

Application No.: 11/106999   Filing Date: 14/Apr/2005

Abstract:

Sterile compositions for administration as aerosols are described. They contain an active agent which is poorly water-soluble, a non-ionic surfactant acomponent and a phospholipid component. The compositions are suitable for oral or nasal inhalation, but also for topical or oromucosal administration. They are particulary useful for the efficient pulmonary administration of poorly soluble corticosteroids and can be aerosolized with common nebulizers.

Priority: DE20031047994 Applic. Date: 2003-10-15; WO2004EP11571 Applic. Date: 2004-10-14

Inventor: JAUERNIG JURGEN [DE]; LINTZ FRANK-CHRISTOPHE [DE]; KELLER MANFRED [DE]; FRIEDRICH INGO [DE]


Patent No.: US7763607B2  Issued: 27/Jul/2010

Title: Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators

Applicant/Assignee: SOLVAY PHARMACEUTICALS GMBH

Application No.: 11/796716   Filing Date: 26/Apr/2007

Abstract:

Described herein are pharmaceutical compositions comprising therapeutically effective quantities of (i) a KATP channel modulator

and (ii) a CBx modulator. Also described herein are methods of making and using these compositions.

Priority: US20060745757P Applic. Date: 2006-04-27; US20060745760P Applic. Date: 2006-04-27

Inventor: ANTEL JOCHEN [DE]; GREGORY PETER-COLIN [DE]; LANGE JOSEPHUS HUBERTUS MARIA [NL]; FIRNGES MICHAEL [DE]; REICHE DANIA [DE]


Patent No.: US7767225B2  Issued: 03/Aug/2010

Title: Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients

Applicant/Assignee: INTERMUNE, INC

Application No.: 12/426182   Filing Date: 17/Apr/2009

Abstract:

A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.

Priority: US2006-067712 Applic. Date: 2006-09-22; WO2006US37057 Applic. Date: 2006-09-22; US20050720257P Applic. Date: 2005-09-22

Inventor: RADHAKRISHNAN RAMACHANDRAN [US]; VLADYKA RONALD [US]; SULTZBAUGH KENNETH [US]


Patent No.: US7767228B2  Issued: 03/Aug/2010

Title: Pharmaceutical composition for oral application and method for preparing thereof

Applicant/Assignee: UDO MATTERN CUM PHARMA CONSULTING ANSTALT

Application No.: 10/794310   Filing Date: 05/Mar/2004

Abstract:

The present invention relates to a pharmaceutical composition for oral application comprising: i) an anthelmintic agent

ii) a first excipient having a porous structure with an inner surface of about 500 to 1500 m2/g and a surface area according to BET of up to about 5000 m2/g

as well as to a method of preparing such a composition.

Priority: EP20040003906 Applic. Date: 2004-02-20

Inventor: MATTERN CLAUDIA [CH]; PIEPER WILFRIED [DE]


Patent No.: US7767231B2  Issued: 03/Aug/2010

Title: Taste-Masking Pharmaceutical Compositions

Applicant/Assignee: SANDOZ AG

Application No.: 11/576890   Filing Date: 10/Oct/2005

Abstract:

The present invention relates to a pharmaceutical composition for oral administration suitable for the preparation of a ready-to-use suspension comprising coated particles comprising an active substance having an unpleasant and/or bitter taste, such as clarithromycin, and a suspension base comprising an osmotically active substance capable of providing a high osmolality to the admixture of the suspension base with an aqueous suspending medium in the ready-to-use suspension. Said ready-to-use suspension maintains its palatability over a prolonged period of time by those defined osmotic conditions.

Priority: GB20040022645 Applic. Date: 2004-10-12; WO2005EP10890 Applic. Date: 2005-10-10

Inventor: SCHWARZ FRANZ XAVER [AT]; KOSILEK IRINA [AT]


Patent No.: US7767655B2  Issued: 03/Aug/2010

Title: HIGH MOLECULAR WEIGHT POLYSACCHARIDE FRACTION FROM ALOE VERA WITH IMMUNOSTIMULATORY ACTIVITY

Applicant/Assignee: THE UNIVERSITY OF MISSISSIPPI UNIVERSITY OF MISSISSIPPI

Application No.: 11/622509   Filing Date: 12/Jan/2007

Abstract:

A complex, water soluble polysaccharide fraction having potent immunostimulatory activity isolated from Aloe vera. The polysaccharide fraction has an apparent molecular weight above 2 million daltons. Its major glycosyl components are glucose, galactose, mannose and arabinose. The invention further includes pharmaceutical compositions containing the instant polysaccharide fraction, optionally in combination with acceptable pharmaceutical carriers and/or excipients. These pharmaceutical compositions may be used to provide immunostimulation to an individual in need of such treatment by administering to such an individual an effective amount of the composition. The polysaccharide fraction is also useful as a component of dietary supplements and as a standardization component of commercial Aloe products.

Priority: US2003-332408 Applic. Date: 2003-08-13; WO2001US21596 Applic. Date: 2001-07-09; US20000217002P Applic. Date: 2000-07-10

Inventor: PASCO DAVID STANLEY [US]; PUGH NIRMAL DEREK [US]; ELSOHLY MAHMOUD [US]; ROSS SAMIR [US]


Patent No.: US7767709B2  Issued: 03/Aug/2010

Title: PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION

Applicant/Assignee: PLIVA-LACHEMA A.S

Application No.: 12/305337   Filing Date: 20/Jun/2007

Abstract:

An oral pharmaceutical composition characterized in that it consists of a suspension of a platinum complex of general formula I, wherein A and A' independently of one another are an NH3 group or an amino or diamino group containing 1 to 18 carbon atoms, B and B' independently of one another are a halogen atom or a hydroxy group or are an -O-C(O)-R or an -O-C(O)-R' group wherein R and R' independently of one another are hydrogen atom, an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group which groups contain 1 to 10 carbon atoms, or functional derivatives of these groups, X and X' independently of one another are a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X and X' together form a dicarboxylate group containing 2 to 20 carbon atoms, in at least one pharmaceutically acceptable vegetable, animal, mineral,

synthetic or semisynthetic oil and/or in at least one pharmaceutically acceptable vegetable, animal, mineral, synthetic or semisynthetic oily substance, in which suspension the content of the platinum complex of general formula I is 0.5 to 50% by weight based on the total weight of the composition, and which suspension optionally contains at least one pharmaceutically acceptable excipient.

Priority: CZ20060000402 Applic. Date: 2006-06-20; WO2007CZ00058 Applic. Date: 2007-06-20

Inventor: FRANC ALES [CZ]; SOVA PETR [CZ]


Patent No.: US7771744B2  Issued: 10/Aug/2010

Title: Bazedoxifene acetate formulations

Applicant/Assignee: WYETH WYETH LLC

Application No.: 11/508801   Filing Date: 23/Aug/2006

Abstract:

Bazedoxifene acetate formulations and compositions thereof having improved properties relating to reduction, elimination, or prevention of polymorphic conversion of bazedoxifene acetate, and processes for making such formulations and compositions. Components used in the formulations and compositions include a filler/diluent, an optional second filler/diluent, an optional antioxidant, a glidant/disintegrant, and a lubricant.

Priority: US20050710761P Applic. Date: 2005-08-24

Inventor: SHAH SYED M [US]; DIORIO CHRISTOPHER R [US]; EHRNSPERGER ERIC C [US]; ALI KADUM A [US]


Patent No.: US7776315B2  Issued: 17/Aug/2010

Title: Pharmaceutical compositions based on anticholinergics and additional active ingredients

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Application No.: 11/006940   Filing Date: 08/Dec/2004

Abstract:

A pharmaceutical composition comprising an anticholinergic and at least one additional active ingredient selected from among corticosteroids, dopamine agonistes, PDE-IV inhibitors, NK1-antagonists, endothelin antagonists, antihistamines, and EGFR-kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

Priority: DE20001054042 Applic. Date: 2000-10-31; DE20001062712 Applic. Date: 2000-12-15; DE20001063957 Applic. Date: 2000-12-20; DE20011010772 Applic. Date: 2001-03-07; DE20011011058 Applic. Date: 2001-03-08; DE20011013366 Applic. Date: 2001-03-20; DE20011038272 Applic. Date: 2001-08-10; DE20021006505 Applic. Date: 2002-02-16; US2004-776757 Applic. Date: 2004-02-11; US2001-086145 Applic. Date: 2001-10-19; US2004-775901 Applic. Date: 2004-02-10; US2001-027662 Applic. Date: 2001-12-20; US2003-613783 Applic. Date: 2003-07-03; US2002-093240 Applic. Date: 2002-03-07; US2004-763894 Applic. Date: 2004-01-23; US2003-419358 Applic. Date: 2003-04-21; US2002-092116 Applic. Date: 2002-03-06; US2003-413065 Applic. Date: 2003-04-14; US2002-100659 Applic. Date: 2002-03-18; US2004-824391 Applic. Date: 2004-04-14; US2001-007182 Applic. Date: 2001-10-19; US2003-360064 Applic. Date: 2003-02-07; US20000257220P Applic. Date: 2000-12-21; US20000253613P Applic. Date: 2000-11-28; US20000257221P Applic. Date: 2000-12-21; US20010281857P Applic. Date: 2001-04-05; US20010281653P Applic. Date: 2001-04-05; US20010281874P Applic. Date: 2001-04-05; US20010314599P Applic. Date: 2001-08-24; US20020369213P Applic. Date: 2002-04-01

Inventor: PAIRET MICHEL [DE]; PIEPER MICHAEL P [DE]; MEADE CHRISTOPHER JOHN MONTAGUE [DE]; REICHL RICHARD [DE]; SCHMELZER CHRISTEL [DE]; JUNG BIRGIT [DE]


Patent No.: US7776358B2  Issued: 17/Aug/2010

Title: Extended release venlafaxine besylate tablets

Applicant/Assignee: SYNTHON IP INC

Application No.: 10/895984   Filing Date: 22/Jul/2004

Abstract:

Venlafaxine besylate is formulated into an extended release tablet in high loading rates by use of a coating that contains ammonio methacrylate copolymer(s).

Priority:

Inventor: CUCALA ESCOI JOAN [ES]; GALLEGO LUENGO MONTSERRAT [ES]; MARGALLO LANA INOCENCIA [ES]


Patent No.: US7780987B2  Issued: 24/Aug/2010

Title: Controlled release dosage forms

Applicant/Assignee: BIOVAIL LABORATORIES INTERNATIONAL SRL

Application No.: 10/370109   Filing Date: 21/Feb/2003

Abstract:

The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55 DEG C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.

Priority: US20020357851P Applic. Date: 2002-02-21

Inventor: ZHOU FANG [US]; MAES PAUL [US]


Patent No.: US7785629B2  Issued: 31/Aug/2010

Title: Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof

Applicant/Assignee: HELM AG

Application No.: 11/156576   Filing Date: 21/Jun/2005

Abstract:

The present invention relates to an adsorbate, comprising an adsorbent and bicalutamide adsorbed on said adsorbent, a process for preparing same, and a pharmaceutical composition thereof.

Priority:

Inventor: GLAENZER KLAUS [DE]


Patent No.: US7786081B2  Issued: 31/Aug/2010

Title: Peptide composition

Applicant/Assignee: PEPSYN LTD

Application No.: 11/502345   Filing Date: 09/Aug/2006

Abstract:

Provided is use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in stimulating fibroblasts to produce fibrillin, wherein the peptide comprises an amino acid sequence present in an [alpha]-S2 casein precursor, said sequence comprising 3 or more amino acids, and not comprising at its N-terminal amino acid of the full [alpha]-S2 casein precursor. Further provided is use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in stimulating fibroblasts to produce fibrillin, wherein the peptide has an [alpha]-S2 casein fragment activity.

Priority: GB20020009384 Applic. Date: 2002-04-24; US2005-512512 Applic. Date: 2005-07-07; WO2003GB01439 Applic. Date: 2003-04-02

Inventor: SMITH JOHN ARTHUR [GB]


Patent No.: US7786095B2  Issued: 31/Aug/2010

Title: Amphiphilic macrocyclic derivatives and their analogues

Applicant/Assignee: UNIVERSITY COLLEGE DUBLIN

Application No.: 11/295724   Filing Date: 07/Dec/2005

Abstract:

Soluble amphiphilic macrocycle analogues having lipophilic groups attached to one side of the units making up the macrocycle and hydrophilic groups attached to the other side. These amphiphilic macrocyclic derivatives have the ability to self-assemble in aqueous solvent forming micelles or vesicles and can be used as hosts for the solubilization and/or stabilization of various compounds. Embodiments of the present invention utilize macrocyclic oligosaccharides and preferably cyclodextrin as the macrocyclic derivatives to be modified.

Priority: IE20000000326 Applic. Date: 2000-04-28; US2002-281070 Applic. Date: 2002-10-25; WO2001IE00057 Applic. Date: 2001-04-30

Inventor: DARCY RAPHAEL [IE]; PENKLER LAWRENCE JOHN [ZA]; RAVOO BART JAN [IE]


Patent No.: US7786168B2  Issued: 31/Aug/2010

Title: PHENOLIC ACID SALTS OF GABAPENTIN IN SOLID DOSAGE FORMS AND METHODS OF USE

Applicant/Assignee: KIEL LABORATORIES, INC

Application No.: 12/138945   Filing Date: 13/Jun/2008

Abstract:

The present invention relates to pharmaceutical compositions of gabapentin tannate in solid dosage form, processes for production of those compositions and methods of use of those compositions. Tannate salts of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. The process may utilize either natural or synthetic tannic acid.

Priority: US2004-805806 Applic. Date: 2004-03-22; US20030457399P Applic. Date: 2003-03-25

Inventor: KIEL JEFFREY S [US]; THOMAS H GREG [US]; MANI NARASIMHAN [US]


Patent No.: US7790140B2  Issued: 07/Sep/2010

Title: COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND OTHER MATERIALS, AND METHODS OF MAKING AND USING THE SAME

Applicant/Assignee: PHARMAIN CORPORATION

Application No.: 11/428803   Filing Date: 05/Jul/2006

Abstract:

In part, the present invention is directed to biocompatible compositions comprising a carrier with a first metal binding domain, a metal ion, an active agent with second metal binding domain and optionally a protective chain covalently attached to the polymeric carrier.

Priority: US2003-378100 Applic. Date: 2003-02-27; US20020360350P Applic. Date: 2002-02-27

Inventor: BOLOTIN ELIJAH M [US]


Patent No.: US7790916B2  Issued: 07/Sep/2010

Title: Carbocyclic and oxacarbocyclic fumaric acid oligomers

Applicant/Assignee: BIOGEN IDEC INTERNATIONAL GMBH

Application No.: 10/511564   Filing Date: 15/Oct/2004

Abstract:

The present invention relates to certain carbocyclic and oxacarbocyclic fumaric acid oligomers and the use thereof for preparing a pharmaceutical preparation as well of pharmaceutical preparations containing these compounds.

Priority: DE20021017314 Applic. Date: 2002-04-18; WO2003EP03498 Applic. Date: 2003-04-03

Inventor: JOSHI RAJENDRA KUMAR [CH]; STREBEL HANS-PETER [CH]


Patent No.: US7799790B2  Issued: 21/Sep/2010

Title: Amorphous Aripiprazole and Process for the Preparation thereof

Applicant/Assignee: HELM AG

Application No.: 12/131618   Filing Date: 02/Jun/2008

Abstract:

Morphologically stabilized amorphous aripiprazole and process for preparing the same.

Priority: EP20060117595 Applic. Date: 2006-07-20; EP20080150576 Applic. Date: 2008-01-23; US2006-463062 Applic. Date: 2006-08-08

Inventor: DREYER KATJA [DE]; LOEFFLER UWE [DE]; GLAENZER KLAUS [DE]


Patent No.: US7803402B2  Issued: 28/Sep/2010

Title: Pharmaceutical preparations

Applicant/Assignee:

Application No.: 10/456690   Filing Date: 06/Jun/2003

Abstract:

A pharmaceutical extended-release oral drug delivery system comprising as active ingredient Cefixime Trihydrate in combination with a hydrophilic matrix system, and optionally containing additional pharmaceutically acceptable constituents, wherein at least 20% up to but not more than 40% of Cefixime Trihydrate is released from said matrix within 1 hour from oral administration and the remainder of the pharmaceutical agent is released at a sustained rate.

Priority: IN2002MU00506 Applic. Date: 2002-07-06

Inventor: KHANDELWAL SANJEEV [IN]; OMRAY PRATIBHA [IN]


Patent No.: US7803840B2  Issued: 28/Sep/2010

Title: UTILIZATION OF DIALKYLFUMARATES

Applicant/Assignee: BIOGEN IDEC INTERNATIONAL GMBH

Application No.: 12/405661   Filing Date: 17/Mar/2009

Abstract:

The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.

Priority: DE19981053487 Applic. Date: 1998-11-19; US2007-765578 Applic. Date: 2007-06-20; US2002-197077 Applic. Date: 2002-07-17; US2001-831620 Applic. Date: 2001-05-10; WO1999EP08215 Applic. Date: 1999-10-29

Inventor: JOSHI RAJENDRA KUMAR [CH]; STREBEL HANS-PETER [CH]


Patent No.: US7807715B2  Issued: 05/Oct/2010

Title: Pharmaceutical compositions comprising fesoterodine

Applicant/Assignee: UCB PHARMA GMBH

Application No.: 11/811327   Filing Date: 07/Jun/2007

Abstract:

The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.

Priority: US20060812149P Applic. Date: 2006-06-09

Inventor: ARTH CHRISTOPH [DE]; KOMENDA MICHAEL [DE]; BICANE FATIMA [DE]; MIKA HANS-JURGEN [DE]


Patent No.: US7811593B2  Issued: 12/Oct/2010

Title: Pharmaceutical composition with combined active agents and methods for using the same

Applicant/Assignee:

Application No.: 10/507382   Filing Date: 09/Sep/2004

Abstract:

The current invention involves a pharmaceutical composition containing a combination of two active agents. The invention also involves the use of the combination composition to the preparation of a drug combination intended to treat, control and prevent type 2 diabetes and other diseases and conditions that glucose abnormality, including abnormalities in glucose levels and glucose metabolism, is a component.

Priority: US20020366684P Applic. Date: 2002-03-25; WO2003US07388 Applic. Date: 2003-03-10

Inventor: LUO JIAN [US]; WU HUI CHANG [US]


Patent No.: US7811604B1  Issued: 12/Oct/2010

Title: Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same

Applicant/Assignee: BARR LABORATORIES, INC

Application No.: 11/598833   Filing Date: 14/Nov/2006

Abstract:

The present invention is directed to non-effervescent, orally disintegrating dosage forms comprising free base clozapine that are substantially free of acids, water-soluble polymers, taste-masking polymers, and coatings, and methods of making and using the same.

Priority: US20050735832P Applic. Date: 2005-11-14

Inventor: AHMED SALAH U [US]; LI LIANLI [US]; CHOWDHURY TAHSEEN A [US]


Patent No.: US7811605B2  Issued: 12/Oct/2010

Title: Method of formation of shape-retentive aggregates of gel particles and their uses

Applicant/Assignee: ULURU INC

Application No.: 10/960461   Filing Date: 06/Oct/2004

Abstract:

The present invention relates to a method of forming shape-retentive aggregates of gel particles in which the aggregates are held together by non-covalent bond physical forces such as, without limitation, hydrophobic-hydrophilic interactions and hydrogen bonds. The method comprises introducing a suspension of gel particles in a polar liquid at a selected concentration, wherein the gel particles have an absolute zeta potential, into a medium in which the absolute zeta potential of the gel particles is decreased, resulting in the gel particles coalescing into the claimed shape-retentive aggregate. This invention also relates to uses of the method of formation of the shape-retentive aggregates of gel particles.

Priority: US2002-289756 Applic. Date: 2002-11-06

Inventor: MORO DANIEL G [US]; ST JOHN JOHN V [US]; SHANNON KEVIN F [US]; PONDER BILL C [US]


Patent No.: US7815937B2  Issued: 19/Oct/2010

Title: Quick dissolve compositions and tablets based thereon

Applicant/Assignee: BIOVAIL BIOVAIL LABORATORIES INTERNATIONAL SRL

Application No.: 10/176135   Filing Date: 21/Jun/2002

Abstract:

The invention provides a composition useful for making oral dosage forms capable of dissolving in the mouth in less than 40 seconds without the need for a conventional super disintegrant and having a friability of less than 1%

wherein the composition includes liquiflash particles and an excipient mass. A preferred excipient mass according to the invention contains a directly compressible inorganic salt

a cellulose derivative or a combination of a directly compressible inorganic salt and a cellulose derivative. Preferably, the liquiflash particles and the excipient mass are combined in proportions such that the active ingredient remains substantially within the microspheres when the composition is compressed to obtain a dosage form having a hardness of 20 to 50 N. The compositions of the invention allow for the fabrication of oral dosages having improved hardness and friability.

Priority: US1998-179926 Applic. Date: 1998-10-27

Inventor: MEZAACHE NAIMA [US]; FRISBEE STEVEN E [US]; WOODALL PATRICK B [US]; HERMAN MARK R [US]; MEZAACHE DJELILA [US]


Patent No.: US7815938B2  Issued: 19/Oct/2010

Title: Film coating

Applicant/Assignee: ASTRAZENECA AB

Application No.: 10/942407   Filing Date: 16/Sep/2004

Abstract:

A film coating composition suitable for use in coating pharmaceutical formulations to provide modified release comprising a dispersion which includes: a) an acrylic polymer, b) a vinyl acetate polymer, and c) a water-containing liquid. The film coat is useful for the achievement of modified release from pharmaceutical formulations such as tablets, pellets, etc.

Priority: WO2002GB05739 Applic. Date: 2002-12-18; SE20010004327 Applic. Date: 2001-12-19; SE20010004328 Applic. Date: 2001-12-19; US2003-450794 Applic. Date: 2003-06-16

Inventor: LOEFROTH JAN-ERIK [SE]; SCHANTZ STAFFAN [SE]; WELIN ANDERS [SE]; HJAERTSTAM LARS JOHAN PONTUS DE VERDIER [DE]


Patent No.: US7815940B2  Issued: 19/Oct/2010

Title: Gastric acid secretion inhibiting composition

Applicant/Assignee: OREXO AB

Application No.: 10/475254   Filing Date: 12/Dec/2003

Abstract:

An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid susceptible proton pump inhibitor or a salt thereof, an H2 receptor antagonist or a salt thereof and a pharmaceutically acceptable carrier. The dosage form is capable of raising gastric pH to above 4 within two hours after administration and to keep it at that level for at least 4 hours. Also disclosed is a method of manufacture of the dosage form, its use in treating dyspepsia and infection by Helicobacter pylori, and a method of treating disorders associated with gastric acid secretion.

Priority: SE20010001379 Applic. Date: 2001-04-18; WO2002SE00757 Applic. Date: 2002-04-17

Inventor: PETTERSSON ANDERS [SE]


Patent No.: US7820684B2  Issued: 26/Oct/2010

Title: PHARMACEUTICAL FORMULATIONS COMPRISING SALTS OF A PROTEIN KINASE INHIBITOR AND METHODS OF USING SAME

Applicant/Assignee: SUPERGEN, INC

Application No.: 12/041565   Filing Date: 03/Mar/2008

Abstract:

The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.

Priority: US20070892373P Applic. Date: 2007-03-01; US20070911789P Applic. Date: 2007-04-13

Inventor: BEARSS DAVID J [US]; JOSHI-HANGAL RAJASHREE [US]; LIU XIAO-HUI [US]; PHIASIVONGSA PASIT [US]; REDKAR SANJEEV G [US]; VANKAYALAPATI HARIPRASAD [US]


Patent No.: US7820701B2  Issued: 26/Oct/2010

Title: Amorphous lercanidipine hydrochloride and uses thereof

Applicant/Assignee: RECORDATI IRELAND LIMITED

Application No.: 11/364862   Filing Date: 27/Feb/2006

Abstract:

The invention provides a substantially pure amorphous lercanidipine hydrochloride having a purity of at least 95% pure, preferably at least about 97% pure, more preferably at least about 99% pure, and still more preferably at least about 99.5% pure. The invention further relates to methods of preparing substantially pure amorphous lercanidipine, as well as methods of providing rapid relief from hypertension by administering the substantially pure amorphous lercanidipine hydrochloride of the present invention to a patient in need of such treatment.

Priority: US20050656836P Applic. Date: 2005-02-25

Inventor: LEONARDI AMEDEO [IT]; MOTTA GIANNI [IT]; BERLATI FABIO [IT]


Patent No.: US7820716B2  Issued: 26/Oct/2010

Title: Crystalline polymorphs of desvenlafaxine succinate and their preparations

Applicant/Assignee: MAI DE LTD

Application No.: 11/982622   Filing Date: 05/Nov/2007

Abstract:

The present invention is directed to two new polymorph Form V and Form F of desvenlafaxine succinate, to processes of their preparations, pharmaceutical composition comprising such materials and their use in therapy. Form V is prepared from recrystallizing desvenlafaxine succinate in a mixture of tetrahydrofuran and ethanol. Form F is obtained from recrystallization of desvenlafaxine succinate in a mixture of cyclohexane and polar solvents such as ethanol, THF, methanol or isopropyl alcohol.

Priority: US20070878983P Applic. Date: 2007-01-08

Inventor: HUANG CAI GU [CN]; HUANG HUI MIN HE [CN]


Patent No.: US7824588B2  Issued: 02/Nov/2010

Title: Method of making self-supporting therapeutic active-containing film

Applicant/Assignee: MONOSOL RX, LLC

Application No.: 12/102071   Filing Date: 14/Apr/2008

Abstract:

The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to temperatures above that at which the active components typically degrade without concern for loss of the desired activity.

Priority: US2004-768809 Applic. Date: 2004-01-30; WO2002US32575 Applic. Date: 2002-10-11; WO2002US32594 Applic. Date: 2002-10-11; WO2002US32542 Applic. Date: 2002-10-11; US20030443741P Applic. Date: 2003-01-30; US20020386937P Applic. Date: 2002-06-07; US20020414276P Applic. Date: 2002-09-27; US20020371940P Applic. Date: 2002-04-11; US20010328868P Applic. Date: 2001-10-12

Inventor: YANG ROBERT K [US]; FUISZ RICHARD C [US]; MYERS GARRY L [US]; FUISZ JOSEPH M [US]


Patent No.: US7825106B2  Issued: 02/Nov/2010

Title: Modified release formulations and methods of treating inflammatory bowel disease

Applicant/Assignee: AGI THERAPEUTICS LTD

Application No.: 11/371958   Filing Date: 10/Mar/2006

Abstract:

Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid, and pharmaceutically acceptable salts and pro-drugs thereof, to affected areas of the intestine, i.e., distal gut. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.

Priority: US2004-930743 Applic. Date: 2004-09-01; US20030499365P Applic. Date: 2003-09-03

Inventor: DEVANE JOHN [IE]; BUTLER JACKIE [IE]


Patent No.: US7825125B2  Issued: 02/Nov/2010

Title: Amorphous Aripiprazole and Process for the Preparation thereof

Applicant/Assignee: HELM AG

Application No.: 11/463062   Filing Date: 08/Aug/2006

Abstract:

Morphologically stabilized amorphous aripiprazole and process for preparing the same.

Priority: EP20060117595 Applic. Date: 2006-07-20

Inventor: STRITZKE KATJA [DE]; LOEFFLER UWE [DE]; GLAENZER KLAUS [DE]


Patent No.: US7834172B2  Issued: 16/Nov/2010

Title: COMPOSITION COMPRISING AT LEAST ONE NUCLEOSIDIC MOIETY AS A THERAPEUTIC AGENT, AND CKC

Applicant/Assignee: NOVAGALI PHARMA SA

Application No.: 11/939840   Filing Date: 14/Nov/2007

Abstract:

Composition comprising at least one nucleosidic moiety and cetalkonium chloride and pharmaceutical use thereof for prevention, treatment or relief of eye, lung, and/or respiratory tract conditions.

Priority:

Inventor: LAMBERT GREGORY [FR]; LALLEMAND FREDERIC [FR]


Patent No.: US7838028B2  Issued: 23/Nov/2010

Title: Pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substance, and respective processes of producing same and a cup-shaped envelope of same

Applicant/Assignee: JAGOTEC AG

Application No.: 10/473055   Filing Date: 30/Mar/2004

Abstract:

A tablet system for prolonged floating in or on gastric fluid for releasing therein pharmaceutically active substances in an alternate succession of substance release and no-release periods is made up of a multilayered core placed in a cup-shaped envelope. The core is made up of release layers and no-release layers devoid of pharmaceutically active substance, superposed in alternate succession. The cup-shaped envelope covers bottom and side surfaces of the core while leaving exposed an upper surface of the core. The cup-shaped envelope provides for buoyancy by being formed of a compression-sintered mixture comprising hydrophobic material and inert powdered filler. The hydrophobic material is composed of fatty and/or waxy material capable of being sintered by compression and whose bulk density is lower than gastric fluid density.

The powdered filler has a loose powder density that is lower than gastric fluid density.

Priority: EP20010108252 Applic. Date: 2001-03-31; WO2002IB00959 Applic. Date: 2002-03-18

Inventor: GRENIER PASCAL [FR]; RICCHI ELISABETH [FR]; QUINTON JACQUES [FR]; VERGNAULT GUY [FR]


Patent No.: US7838030B2  Issued: 23/Nov/2010

Title: COMPOSITIONS FOR ORAL USE BASED ON S-ADENOSYLMETHIONINE AND A PROCESS FOR THEIR PREPARATION

Applicant/Assignee: TRUFFINI & REGGE' FARMACEUTICI SPA GRAAL SR:L

Application No.: 11/276900   Filing Date: 17/Mar/2006

Abstract:

The present invention relates to solid dietary and/or nutraceutic pharmaceutical compositions for oral use based on SAMe, or salts thereof, in combination with inositol and/or derivatives thereof and to a process for their preparation. The present invention relates to a method of stabilising a solid composition for oral use based on SAMe or salts thereof, making use of inositol and/or derivatives thereof with the addition of magnesium oxide.

Priority: IT2006MI00026 Applic. Date: 2006-01-10

Inventor: SENECI ALESSANDRO [IT]; GIOVANNONE DANIELE [IT]; ZIO CESARE [IT]


Patent No.: US7838532B2  Issued: 23/Nov/2010

Title: Aerosolized fluoroquinolones and uses thereof

Applicant/Assignee: MPEX PHARMACEUTICALS, INC

Application No.: 11/436875   Filing Date: 18/May/2006

Abstract:

Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.

Priority: US20050682530P Applic. Date: 2005-05-18; US20050696160P Applic. Date: 2005-07-01; US20060773300P Applic. Date: 2006-02-13; US20060773301P Applic. Date: 2006-02-13

Inventor: SURBER MARK W [US]; BOSTIAN KEITH A [US]; DUDLEY MICHAEL N [US]; LOMOVSKAYA OLGA [US]; GRIFFITH DAVID C [US]


Patent No.: US7838534B2  Issued: 23/Nov/2010

Title: Quinuclidine derivatives as M3 antagonists

Applicant/Assignee: CHIESI FARMACEUTICI S.P.A

Application No.: 11/881146   Filing Date: 25/Jul/2007

Abstract:

Quinuclidine derivative of the general formula (I) in the form of single enantiomers or mixtures thereof are useful in the manufacture of a medicament for the prevention and therapy of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, cough and emphysema wherein: R1 is selected from H, F, Cl, Br, I and (C1-C4)-alkyl

R2 is optionally substituted 2- or 3-thienyl, or substituted phenyl

R3 is (CH2)1-4-COR4 or (CH2)1-4-S(O)nR4, wherein R4 is optionally substituted phenyl or optionally substituted 2- or 3-thienyl

n is 0, 1 or 2

X- is a pharmaceutically acceptable anion.

Priority: EP20060117883 Applic. Date: 2006-07-26

Inventor: AMARI GABRIELE [IT]; RIZZI ANDREA [IT]; PATACCHINI RICCARDO [IT]; CENACCHI VALENTINA [IT]; VILLETTI GINO [IT]; CATENA RUIZ JUAN LORENZO [IT]; MASIP MASIP ISABEL [IT]


Patent No.: US7842308B2  Issued: 30/Nov/2010

Title: Pharmaceutical formulation

Applicant/Assignee: SMITHKLINE BEECHAM LIMITED

Application No.: 10/470439   Filing Date: 20/Jan/2004

Abstract:

The present invention is directed to pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.

Priority: GB20010002342 Applic. Date: 2001-01-30; WO2002US02698 Applic. Date: 2002-01-30

Inventor: MCALLISTER STEPHEN MARK [GB]; RABY JR RONALD K [US]; BROWN ADRIAN [GB]; CLARKE ALLAN J [US]


Patent No.: US7842495B2  Issued: 30/Nov/2010

Title: Lactic acid bacteria capable of stimulating mucosal immunity

Applicant/Assignee: OTSUKA PHARMACEUTICAL CO., LTD

Application No.: 10/568671   Filing Date: 17/Feb/2006

Abstract:

The invention provides lactic acid bacteria selected from the group consisting of lactobacillus ONRIC b0239 (FERM BP-10064) and lactobacillus ONRIC b0240 (FERM BP-10065), and compositions containing the bacteria, the compositions being capable of stimulating mucosal immunity, and more specifically, the compositions in the form of foods or beverages or pharmaceutical products. The lactic acid bacteria and compositions containing the bacteria are capable of providing excellent mucosal immunostimulation effects and are useful for reinforcing the host defense system.

Priority: JP20030297570 Applic. Date: 2003-08-21; WO2004JP12136 Applic. Date: 2004-08-18

Inventor: YAMAHIRA SATOKO [JP]; TOBA MASAMICHI [JP]; OKAMATSU HIROSHI [JP]


Patent No.: US7842679B2  Issued: 30/Nov/2010

Title: PHOSPHOLIPID DERIVATIVES OF DHA AND METHODS FOR TREATING RESPIRATORY FAILURE USING THE SAME

Applicant/Assignee:

Application No.: 12/040958   Filing Date: 03/Mar/2008

Abstract:

Taught are pharmaceutical compositions comprising at least one phospholipid having at least one docosahexaenoyl (DHA) residue, such as a lecithin-DHA-type phospholipid, and methods for treating or preventing respiratory failure of a patient comprising administering these pharmaceutical compositions to a patient in need of such treatment or prevention.

Priority: FR20050008956 Applic. Date: 2005-09-01; WO2006FR01988 Applic. Date: 2006-08-25

Inventor: PIERONI GERARD [FR]; COSTE THIERRY [FR]


Patent No.: US7842706B2  Issued: 30/Nov/2010

Title: Pharmaceutical composition

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY, LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 12/382691   Filing Date: 20/Mar/2009

Abstract:

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Priority: JP19950153500 Applic. Date: 1995-06-20; US2006-523771 Applic. Date: 2006-09-20; US2004-937494 Applic. Date: 2004-09-10; US2003-462793 Applic. Date: 2003-06-17; US2002-095453 Applic. Date: 2002-03-13; US2001-973689 Applic. Date: 2001-10-11; US1999-453521 Applic. Date: 1999-12-03; US1999-280710 Applic. Date: 1999-03-30; US1998-057465 Applic. Date: 1998-04-09; US1996-667979 Applic. Date: 1996-06-19

Inventor: IKEDA HITOSHI [JP]; SOHDA TAKASHI [JP]; ODAKA HIROYUKI [JP]


Patent No.: US7846460B2  Issued: 07/Dec/2010

Title: Composition comprising a mixture of active principles, and method of preparation

Applicant/Assignee: ETHYPHARM

Application No.: 10/544311   Filing Date: 21/Jan/2004

Abstract:

Active principle-based coated particle, in which both the core and the coating contain active principle, includes a core which contains a first active principle while the coating contains a second active principle, which is different in nature.

Priority: FR20030001308 Applic. Date: 2003-02-05; US20030447198P Applic. Date: 2003-02-13; WO2004EP50035 Applic. Date: 2004-01-21

Inventor: CHENEVIER PHILIPPE [CA]; MARECHAL DOMINIQUE [CA]


Patent No.: US7850988B2  Issued: 14/Dec/2010

Title: CALCIUM CARBONATE GRANULATION

Applicant/Assignee: DELAVAU LLC

Application No.: 11/552897   Filing Date: 25/Oct/2006

Abstract:

Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.

Priority: US2003-631923 Applic. Date: 2003-07-31

Inventor: LANG KEVIN W [US]; DIBBLE JAMES W [US]; LEVIN RAYA [US]; MURPHY GREGORY B [US]


Patent No.: US7851483B2  Issued: 14/Dec/2010

Title: Medicaments comprising steroids and a novel anticholinergic

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Application No.: 11/407735   Filing Date: 20/Apr/2006

Abstract:

A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X- is an anion with a single negative charge

and (b) a steroid 2, processes for preparing such pharmaceutical composition, and their use in the treatment of respiratory complaints.

Priority: DE20021016429 Applic. Date: 2002-04-12; US2003-391735 Applic. Date: 2003-03-19; US20020386790P Applic. Date: 2002-06-07

Inventor: BANHOLZER ROLF [DE]; MEISSNER HELMUT [DE]; MORSCHHAEUSER GERD [DE]; PIEPER MICHAEL P [DE]; POHL GERALD [DE]; REICHL RICHARD [DE]; SPECK GEORG [DE]; MEADE CHRISTOPHER JOHN MONTAGUE [DE]; PAIRET MICHEL [DE]


Patent No.: US7858077B2  Issued: 28/Dec/2010

Title: Functionalized phenolic esters and amides and polymers therefrom

Applicant/Assignee: BEZWADA BIOMEDICAL LLC

Application No.: 11/220044   Filing Date: 06/Sep/2005

Abstract:

The present invention relates to a compound of the formula: R-AR-O-Y-R' Wherein R represents one or more members selected from H, alkoxy, benzyloxy, aldehyde, halogen, carboxylic acid, -NO2, -NH2, -NHCOCH3, and -NH-Y-R', which is attached directly to AR or attached through an aliphatic chain. The carboxylic acid moiety in R includes but is not limited to the following carboxylic acids: benzoic acids, cinnamic acids, ferulic acid, caffeic acid, syringic acid, salicylic acid, vanillic acid, phenylacetic acids, phenylpropionic acids, and sinapinic acid. -AR-O- is a biologically active phenolic moiety comprising 1 to 6 substituted or unsubstituted aryl rings that are directly bonded to each other, fused together, or joined through a linking group. Y represents a member selected from: -COCH2O- (glycolic ester moiety) -COCH(CH3)O- (lactic ester moiety) -COCH2OCH2CH2O- (dioxanone ester moiety) -COCH2CH2CH2CH2CH2O- (caprolactone ester moiety) -CO(CH2)mO- where m is an integer between 2-4 and 6-24 inclusive -COCH2O(CH2CH2O)n- where n is an integer between 2 and 24, inclusive

and R' is either hydrogen or a benzyl or an alkyl group, the alkyl group being either straight-chained or branched. The resultant functionalized phenolic compounds, used singly or in combinations, and their polymers have controllable degradation profiles, releasing the active component over a desired time range. The polymers are useful for biomaterials and biomedical devices, wherein said biologically active phenolic moiety is a residue of a phenolic compound.

Priority: US20050647996P Applic. Date: 2005-01-28

Inventor: BEZWADA RAO S [US]


Patent No.: US7858119B1  Issued: 28/Dec/2010

Title: Extended release pharmaceuticals

Applicant/Assignee:

Application No.: 09/845497   Filing Date: 01/May/2001

Abstract:

An extended release pharmaceutical formulation is disclosed. A selected pharmaceutical agent is encased within polymeric film layers providing for gradual release of the pharmaceutical active for over 12 and even 24 hours in the gastrointestinal tract and the blood plasma.

Priority: US20000203049P Applic. Date: 2000-05-09

Inventor: ODIDI AMINA [CA]; ODIDI ISA [CA]


Patent No.: US7858126B2  Issued: 28/Dec/2010

Title: Derivatives of sandalwood oil and santalols for treating cold sores and herpes

Applicant/Assignee: TRINITY LABORATORIES INC

Application No.: 11/896327   Filing Date: 31/Aug/2007

Abstract:

The present invention relates to the formulations of ester derivatives of sandalwood oil and santalol. These derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis. These derivatives have a higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound, and hence are better able to be incorporated into certain pharmaceutical formulations, including cream and ointment pharmaceutical formulations. The compounds of the present invention are set forth by the following formula: The present invention generally pertains to a compound of formula (I): R-CO-SWO (I) wherein SWO refers to collectively the alcohols, including santalol, present in the sandalwood oil

wherein R is selected from alkyl groups of up to about 22 carbon atoms and aryl groups of up to about 22 carbon atoms and alkylene group of up to about 22 carbon atoms and an arylene group of up to about 22 carbon atoms. The alkyl, aryl and alkylene groups may be substituted or unsubstituted, branched or straight chains. In addition, R may contain heteroatoms and may be straight chained or branched. Compounds of formula I are useful as anti-bacterial and anti-viral in mammals in vivo and have been contemplated to be used in the treatment of skin disease.

Priority: US20060841228P Applic. Date: 2006-08-31

Inventor: SINGH CHANDRA ULAGARAJ [US]; NULU JAGAVEERABHADRA RAO [US]


Patent No.: US7858594B2  Issued: 28/Dec/2010

Title: Crystalline and amorphous forms of beta-L-2'-deoxythymidine

Applicant/Assignee: NOVARTIS AG NOVARTIS PHARMA AG

Application No.: 12/505839   Filing Date: 20/Jul/2009

Abstract:

Physical forms of beta-L-2'-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2'-deoxythymidine can be used in the manufacture of other forms of beta-L-2'-deoxythymidine, or in pharmaceutical compositions. Particularly preferred uses are in the treatment of hepatitis B.

Priority: US2007-807232 Applic. Date: 2007-05-25; US2003-636349 Applic. Date: 2003-08-06; US20020401318P Applic. Date: 2002-08-06

Inventor: JONAITIS DAVID [US]; STORER RICHARD [GB]


Patent No.: US7858663B1  Issued: 28/Dec/2010

Title: Physical and chemical properties of thyroid hormone organic acid addition salts

Applicant/Assignee: PISGAH LABORATORIES, INC

Application No.: 11/932336   Filing Date: 31/Oct/2007

Abstract:

A pharmaceutical composition comprising the salt of a thyroid hormone selected from the group consisting of levothyroxine and liothyronine and an organic acid comprising at least one aromatic ring having at least one hydroxyl moiety and at least one carboxylic acid moiety in an ortho relationship.

Priority:

Inventor: BRISTOL DAVID WILLIAM [US]; KING CLIFFORD RILEY [US]; AUDIA VICKI HAYNES [US]

US Patents Granted in 2011
US Patents Granted in 2009
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..
LIST OF US PATENTS IN EXCIPIENTS, DELIVERY AND RELEASE OF PHARMACEUTICAL COMPOSITIONS GRANTED IN 2010
This list includes patents granted in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms included pharmaceutical
formulations, excipients, strips, gums, cellulose, lozenge, tablets, capsules, suppositories; solid dosage, nasal inhalation; time, control or sustained drug release; polysaccharides,
polymeric excipients, hyaluronic acid, micro- and nano-spheres, carbomer, povidone, polyacrylates, polymerthacrylates; emulsions; enemas, vaginal, rectal, nasal, ocular or buccal
administration of medications and related subjects.
Clck to enlarge and view details